Search
forLearn
5 / 801 resultslearn Biotinyl-GHK
learn LHA™
learn H3-Grow+ Complex™
learn histidine
Research
5 / 415 resultsresearch Pharmacological investigation of vitamin E with combined oral contraceptives on INHBA gene against PCOS that intricate through melatonin PKC pathway
Vitamin E with oral contraceptives helps reduce PCOS symptoms by affecting hormone levels and stress.
research DEFINING THE ROLE OF ABI1 GENE IN PROSTATE CANCER PROGRESSION AND TREATMENT RESISTANCE
The ABI1 gene contributes to prostate cancer progression and treatment resistance.
research Identification of key genes and signaling pathways related to Hetian sheep wool density by RNA-seq technology
Certain genes and pathways are linked to the production of finer and denser wool in Hetian sheep.
research Trial Treatment of Androgenetic Alopecia with Oxidizing Agents (Inaba and Inaba 1984)
Lightly perming scalp hair can lead to new hair growth, potentially treating baldness.
research Impact of One-Week Administration of Dihydrotestosterone in Rat Anterior Pituitary Gland
Dihydrotestosterone changes some hormone-related gene expressions in rat pituitary glands but doesn't affect the estrous cycle.
Community Join
5 / 1000+ resultscommunity HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
community Han Bio Planning Hair Multiplication Trial This Year?
Han Bio plans to start clinical trials for a new hair multiplication technology this year, which could significantly reduce the cost and time of hair transplantation. The technology uses a single hair strand to cultivate enough cells for 30,000 hair strands.
community What's going on with hmi115? The Phase 2 was concluded Nov2024 but no news
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
community Is hmi 115 the cure? Or is it 🧢 just like cosmeRNA, brezula, pyrilutamide, and other 📞 ies
HMI 115 is being discussed as a potential hair loss treatment, with skepticism due to past disappointments like cosmeRNA, brezula, and pyrilutamide. The user is questioning if they should be hopeful for new developments in the next six years.